Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-TechneTECH +0.06%88 Market Cap is $11,240 Mil as of Aug. 03, 2026. GuruFocus rates TECH with a GF Score™ of 88/100 and a GF Value™ of $72.79 (Fairly Valued). The stock has 8 warning signs investors should review. Among 1,423 Biotechnology companies, Bio-Techne ranks better than 97.89% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Bio-Techne's share price for the quarter that ended in Mar. 2026 was $52.26. Bio-Techne's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 157 Mil. Therefore, Bio-Techne's market cap for the quarter that ended in Mar. 2026 was $8,180 Mil.
Bio-Techne's quarterly market cap
increased
from Sep. 2025 ($8,664 Mil) to Dec. 2025 ($9,167 Mil) but then
declined
from Dec. 2025 ($9,167 Mil) to Mar. 2026 ($8,180 Mil).
Bio-Techne's annual market cap
declined
from Jun. 2023 ($12,868 Mil) to Jun. 2024 ($11,336 Mil) and
declined
from Jun. 2024 ($11,336 Mil) to Jun. 2025 ($7,973 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Bio-Techne's Enterprise Value for Today is $11,321 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Bio-Techne Market Cap Related Terms
Bio-Techne Market Cap Historical Data
* Premium members only.
The historical data trend for Bio-Techne's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Techne's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Market Cap distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Bio-Techne's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (TECH) has a Market Cap of $11,240 Mil as of Aug. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bio-Techne and its competitors. According to the industry distribution chart, Bio-Techne ranks #30 out of 1423 companies in the Biotechnology industry, placing it in the top 2.1%.
Is Bio-Techne's Market Cap too high?
Bio-Techne's current Market Cap is $11,240 Mil. The Biotechnology industry median Market Cap is 113.28. Bio-Techne's value of $11,240 Mil is 9822.1% above this industry median. Based on the distribution chart, Bio-Techne ranks #30 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Techne has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Market Cap compare to CYTK and SMMT?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #30 out of 1423 companies for Market Cap. This places Bio-Techne in the top 2% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.28. Bio-Techne's value of $11,240 Mil is 9822.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.28, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Techne's current Market Cap of $11,240 Mil is 9822.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bio-Techne and its competitors. For the Biotechnology industry, the median Market Cap is 113.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Techne's current Market Cap is $11,240 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (TECH) is currently considered Fairly Valued. The stock's GF Value™ is $72.79, compared to a current price of $72.14 — trading 0.9% below its estimated fair value. The current Market Cap is $11,240 Mil and 9822.1% above the Biotechnology industry median of 113.28. Bio-Techne's overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Bio-Techne (TECH), the current Market Cap is $11,240 Mil as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of $72.14 is trading 0.9% below its estimated GF Value™ of $72.79.
GuruFocus considers Bio-Techne to be Fairly Valued.
Key valuation signals for TECH:
Market Cap: $11,240 Mil
GF Value™: $72.79 vs. price of $72.14 (0.9% below fair value)
Industry Position: 9822.1% above the Biotechnology median (#30 of 1423)
No single metric tells the full story. See the TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
88GF Score
Get the complete analysis for TECH
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TECH has been successfully added to your 
